Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Co-stimulatory receptor antibodies activate T cells or antigen-presenting cells through OX40, 4-1BB, CD40 and CD27. Most of these receptors belong to the tumor necrosis factor receptor superfamily (TNFRSF) and signal after clustering, so antibody format and Fc receptor binding shape activity. Urelumab and utomilumab are agonists of 4-1BB (CD137), and varlilumab targets CD27 on lymphocytes. Selicrelumab activates CD40 on dendritic cells and B cells, supporting antigen presentation in immune-priming models. Antibodies to glucocorticoid-induced TNFR-related protein (GITR), inducible T-cell co-stimulator (ICOS) and CD28 complete the group.
Synonyms: R 4930; huMAb OX 40L; Ro 49-89991
Oxelumab (R 4930) is a human monoclonal antibody specifically targeting the OX40 ligand (OX40L). This antibody is utilized primarily in the study of asthma, offering a precise tool for investigating the role of OX40L in immune modulation and inflammatory responses associated with this respiratory condition.
Synonyms: PF 05082566
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody designed for selective binding to 4-1BB/CD137, a costimulatory receptor involved in the regulation of immune cell activation and survival. This antibody has potential applications in oncology research, particularly in the study of follicular and other CD20+ non-Hodgkin lymphomas, where it may enhance antitumor immune responses.
Givastomig is a monoclonal antibody designed to target and inhibit the activity of TNFRSF9/CLDN18. This biologic is engineered for specificity against TNFRSF9/CLDN18, making it suitable for research applications focused on understanding the role of this receptor in disease processes and therapeutic interventions.
Gimistotug is a humanized IgG1κ monoclonal antibody specifically targeting TNFRSF4. For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.
Synonyms: JTX 2011
Vopratelimab (JTX-2011) is a humanized IgG1-kappa agonist monoclonal antibody designed to selectively target the Inducible T-cell CO-Stimulator (ICOS), a critical molecule in the modulation of T-cell activity. This antibody exhibits strong species cross-reactivity, demonstrating binding affinities of 0.93 nM for human ICOS, 0.46 nM for cynomolgus ICOS, 3.7 nM for rat ICOS, and 0.64 nM for murine ICOS. Vopratelimab is primarily utilized in research focused on enhancing antitumor immune responses, making it a valuable tool in oncology and immunotherapy studies.
Synonyms: MEDI 0562; Tavolimab
Tavolixizumab, also known as MEDI 0562 or Tavolimab, is a human monoclonal antibody that targets TNFRSF4 (TNF receptor superfamily member 4). This antibody is specifically designed for research applications in cancer immunology, focusing on the modulation of immune responses in oncological studies. Tavolixizumab binds selectively to TNFRSF4, a receptor implicated in the co-stimulation of T cells, playing a crucial role in immune regulation and potential anti-tumor activity. This product is ideal for researchers studying the mechanisms of immune activation and its effects on cancer progression.
Xirestomig is a monoclonal antibody targeting TNFRSF9 and CD274. This antibody is designed for specificity against these tumor necrosis factor receptor superfamily member 9 and programmed death-ligand 1 (PD-L1), implicated in immune response modulation. Xirestomig is utilized primarily in research focusing on the mechanisms of immune checkpoint regulation and potential therapeutic interventions in cancer immunotherapy.
Vonlerizumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target TNFRSF4, also known as OX40 or CD134. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 145.22 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. Vonlerizumab is applicable in research focused on the modulation of immune responses, particularly in the context of cancer immunotherapy and autoimmune diseases.
Synonyms: TGN1412
Theralizumab (TGN1412) is a humanized IgG4 monoclonal antibody with superagonistic properties targeting CD28. It directly stimulates T-cell activation, which can lead to cytokine release syndrome (CRS). This antibody is primarily utilized in research focused on understanding and potentially treating rheumatoid arthritis.
Synonyms: BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody
Teneliximab (BMS-224819) is a chimeric monoclonal antibody designed to inhibit the interaction between CD40 and CD40L. This antibody exhibits partial agonist activity, enabling limited signaling through CD40. Additionally, Teneliximab facilitates the depletion of peripheral B cells, making it a valuable tool for research into immune system modulation and potential therapeutic applications targeting B cell-mediated disorders.
Ivuxolimab is a monoclonal antibody that acts as an agonist to OX40, also identified as CD134 or TNFRSF4. This costimulatory receptor is predominantly expressed on activated CD4+ and CD8+ T cells. The antibody is designed to enhance immune responses and has demonstrated significant antitumor activity, suggesting its utility in immunotherapy applications.
Synonyms: KY1005; SAR445229
Amlitelimab is a monoclonal antibody targeting the OX40 Ligand (OX40L). By inhibiting the interaction between OX40 and OX40L, Amlitelimab serves as a valuable tool in the study of atopic dermatitis. This antibody's specificity for OX40L makes it ideal for research applications focused on elucidating the role of this ligand-receptor interaction in immune responses and inflammation associated with dermatological disorders.
